Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Joseph McGraw, Armin Gerhardt & Tommy C. Morris. (2018) Opportunities and obstacles in genotypic prediction of cytochrome P450 phenotypes. Expert Opinion on Drug Metabolism & Toxicology 14:7, pages 659-661.
Read now
Read now
Wanaporn Charoenchokthavee, Nutthada Areepium, Duangchit Panomvana & Virote Sriuranpong. (2017) Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients. Breast Cancer: Targets and Therapy 9, pages 249-256.
Read now
Read now
Wanaporn Charoenchokthavee, Duangchit Panomvana, Virote Sriuranpong & Nutthada Areepium. (2016) Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment. Breast Cancer: Targets and Therapy 8, pages 149-155.
Read now
Read now
Bifeng Gao, An Doan & Brooks M Hybertson. (2014) The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders. Clinical Pharmacology: Advances and Applications 6, pages 19-34.
Read now
Read now
Susan E. McCann, Stephen B. Edge, David G. Hicks, Lilian U. Thompson, Carl D. Morrison, Gerald Fetterly, Christopher Andrews, Kim Clark, John Wilton & Swati Kulkarni. (2014) A Pilot Study Comparing the Effect of Flaxseed, Aromatase Inhibitor, and the Combination on Breast Tumor Biomarkers. Nutrition and Cancer 66:4, pages 566-575.
Read now
Read now
Articles from other publishers (15)
Victoria M. Pratt & Stuart A. Scott. 2024. Diagnostic Molecular Pathology. Diagnostic Molecular Pathology
655
667
.
Shingirai M. Chiwambutsa, Oluwatosin Ayeni, Nyasha Kapungu, Comfort Kanji, Roslyn Thelingwani, Wenlong Carl Chen, Dikeledi H. Mokone, Daniel S. O'Neil, Alfred I. Neugut, Judith S. Jacobson, Paul Ruff, Herbert Cubasch, Maureen Joffe & Collen Masimirembwa. (2023) Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co‐Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer. Clinical Pharmacology & Therapeutics 114:1, pages 127-136.
Crossref
Crossref
Tessa A. M. Mulder, Mirjam de With, Marzia del Re, Romano Danesi, Ron H. J. Mathijssen & Ron H. N. van Schaik. (2021) Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy. Cancers 13:4, pages 771.
Crossref
Crossref
Maroua Boujemaa, Yosr Hamdi, Nesrine Mejri, Lilia Romdhane, Kais Ghedira, Hanen Bouaziz, Houda El Benna, Soumaya Labidi, Hamza Dallali, Olfa Jaidane, Sonia Ben Nasr, Abderrazek Haddaoui, Khaled Rahal, Sonia Abdelhak, Hamouda Boussen & Mohamed Samir Boubaker. (2021) Germline copy number variations in BRCA1/2 negative families: Role in the molecular etiology of hereditary breast cancer in Tunisia. PLOS ONE 16:1, pages e0245362.
Crossref
Crossref
Miguel Quintela-Fandino, Juan V. Apala, Diego Malon, Silvana Mouron, Javier Hornedo, Lucia Gonzalez-Cortijo, Ramon Colomer & Juan Guerra. (2019) Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition. Breast Cancer Research 21:1.
Crossref
Crossref
Jemal Hussien Ahmed, Eyasu Makonnen, Alan Fotoohi, Abraham Aseffa, Rawleigh Howe & Eleni Aklillu. (2019) CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients. Cancers 11:9, pages 1353.
Crossref
Crossref
Abdel B. Halim. 2019. Biomarkers, Diagnostics and Precision Medicine in the Drug Industry. Biomarkers, Diagnostics and Precision Medicine in the Drug Industry
241
273
.
Kristin J. R. Dickschen, Stefan Willmann, Georg Hempel & Michael Block. (2017) Addressing Adherence Using Genotype-Specific PBPK Modeling—Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels. Frontiers in Pharmacology 8.
Crossref
Crossref
V.M. Pratt & S.A. Scott. 2017. Diagnostic Molecular Pathology. Diagnostic Molecular Pathology
503
513
.
Suzana Fonseca, António Amorim, Heloísa Afonso Costa, João Franco, Maria João Porto, Jorge Costa Santos & Mário Dias. (2016) Sequencing CYP2D6 for the detection of poor-metabolizers in post-mortem blood samples with tramadol. Forensic Science International 265, pages 153-159.
Crossref
Crossref
Cristina Amaral, Andreia Lopes, Carla L. Varela, Elisiário Tavares da Silva, Fernanda M.F. Roleira, Georgina Correia-da-Silva & Natércia Teixeira. (2015) Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy: A comparative study with Exemestane. The International Journal of Biochemistry & Cell Biology 69, pages 183-195.
Crossref
Crossref
Hiltrud Brauch & Matthias Schwab. (2014) Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer. British Journal of Clinical Pharmacology 77:4, pages 695-703.
Crossref
Crossref
Pierre BaumannPilar H SaladoresMatthias Schwab. 2014. CYP2D6: Genetics, Pharmacology and Clinical Relevance. CYP2D6: Genetics, Pharmacology and Clinical Relevance
42
52
.
Jana C. Precht, Werner Schroth, Kathrin Klein, Hiltrud Brauch, Evgeny Krynetskiy, Matthias Schwab & Thomas E. Mürdter. (2013) The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7. Drug Metabolism and Disposition 41:11, pages 1906-1913.
Crossref
Crossref
José Albuquerque, Carolina Ribeiro, Maria Eugenia G Naranjo, Adrián Llerena & Manuela Grazina. (2013)
Characterization of
CYP2D6
genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications
. Personalized Medicine 10:7, pages 709-718.
Crossref
Crossref